Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:59:07.707Z.
Calculation as of: 2026-10-06T20:59:07.707Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Veraxa Biotech Holding AG
Market Cap
$152.72M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.58M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.01M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$149.36M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.73M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.64M
EV/EBITDA Ratio
N/A
TTM Avg
11.98x
3Y Avg
6.17x
5Y Avg
5.29x
Market Cap
$148.27M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veraxa Biotech Holding AG (VRXA) | $152.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
| Neuronetics, Inc. (STIM)vs › | $153.79M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.22M | N/A | 29.09x | 58.55x | 59.27x |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | N/A | 11.98x | 6.17x | 5.29x |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
